Berlin The diabetes drug Mounjaro is considered one of the most promising new launches in the pharmaceutical industry this year. Manufacturer Eli Lilly is currently marketing the prescription drug in the United States. In Europe, the US group expects approval by the end of the year, and from 2023 the syringe with the active ingredient tirzepatide could also be available in Germany against diabetes on medical prescription.
Eli Lilly CEO Dave Ricks does not want to announce his sales expectations for Mounjaro. But one thing he quickly made clear in an interview with the Handelsblatt: “Mounjaro is a huge growth opportunity for our company.” The analysts at Mizuho are forecasting peak sales of ten billion dollars for the pre-filled syringe for self-injection – and that alone for use against diabetes.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue